Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations

Wuwu Ding,Pengmin Yang,Xiaokai Zhao,Xiaozhi Wang,Huaqing Liu,Qing Su,Xintao Wang,Jieyi Li,Ziying Gong,Daoyun Zhang,Xinwei Wang

DOI: https://doi.org/10.1186/s12931-023-02656-3

IF: 5.8

2024-01-18

Respiratory Research

Abstract:Abstract Background Although EGFR-TKI resistance mechanisms in non-small cell lung cancer (NSCLC) have been extensively studied, certain patient subgroups remain with unclear mechanisms. This retrospective study analysed mutation data of NSCLC patients with EGFR -sensitive mutations and high programmed death-ligand 1 (PD-L1) expression or high TMB to identify primary resistance mechanisms. Methods Hybrid capture-based next-generation sequencing (NGS) was used to analyse mutations in 639 genes in tumor tissues and blood samples from 339 NSCLC patients. PD-L1 immunohistochemical staining was also performed on the same cell blocks. Molecular and pathway profiles were compared among patient subgroups. Results TMB was significantly higher in lung cancer patients with EGFR -sensitive mutations and high PD-L1 expression. Compared with the high-expression PD-L1 or high TMB and low-expression or TMB groups, the top 10 genes exhibited differences in both gene types and mutation rates. Pathway analysis revealed a significant mutations of the PI3K signaling pathway in the EGFR -sensitive mutation group with high PD-L1 expression (38% versus 12%, p < 0.001) and high TMB group (31% versus 13%, p < 0.05). Notably, PIK3CA and PTEN mutations emerged as the most important differentially mutated genes within the PI3K signaling pathway. Conclusions Our findings reveal that the presence of PI3K signaling pathway mutations may be responsible for inducing primary resistance to EGFR-TKIs in NSCLC patients with EGFR -sensitive mutations along with high PD-L1 expression or high TMB. This finding is of great significance in guiding subsequent precision treatments in NSCLC.

respiratory system

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the specific mechanisms of primary resistance to epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR - TKIs) in non - small - cell lung cancer (NSCLC) patients with EGFR - sensitive mutations and high programmed death - ligand 1 (PD - L1) expression or high tumor mutational burden (TMB). Although EGFR - TKIs have shown good effects in treating NSCLC patients with EGFR - sensitive mutations, there are significant differences in the response duration and survival time of some patients, especially in the subgroups of patients with high PD - L1 expression or high TMB, and the prognosis of these patients is poor. Therefore, by retrospectively analyzing the genetic mutation data of these subgroups of patients, especially by comparing the pathway mutation situations among different subgroups, the researchers aim to reveal the potential mechanisms that lead to primary resistance to EGFR - TKIs in these patients, thereby providing new opportunities for subsequent precision treatment. Specifically, the study found that mutations in the phosphatidylinositol - 3 - kinase (PI3K) signaling pathway may induce primary resistance to EGFR - TKIs in NSCLC patients with EGFR - sensitive mutations and high PD - L1 expression or high TMB. The PI3K signaling pathway plays an important role in tumor development and progression, and its abnormal activation is closely related to the occurrence and development of various cancers. The results of the study show that PIK3CA and PTEN gene mutations in the PI3K signaling pathway are more common in these subgroups of patients, which may be one of the reasons for the poor response of these patients to EGFR - TKIs.

Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations

Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study

P3.02b-118 Potential Mechanism Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to EGFR-TKIs: Topic: EGFR RES

Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Novel Resistance Mechanisms to First Generation EGFR Tyrosine Kinase Inhibitors: A Perspective Study in NSCLC Patients Using Targeted Next Generation Sequencing.

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (Tkis).

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway

Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing

Circulating Tumor-Dna Profiling to Reveal Heterogeneity of EGFR-TKI Resistance Mechanisms in Lung Adenocarcinoma Patients.

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations

Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors

[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs]

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Identification of Plasma Microrna Profiles for Primary Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Activating Mutation.

Potential Resistance Mechanisms Using Next Generation Sequencing from Chinese EGFR T790M+ Non-Small Cell Lung Cancer Patients with Primary Resistance to Osimertinib: A Multicenter Study

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer